相关临床试验
52
44 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1913
进行中（未招募）
44
84.6%
已完成
8
15.4%
暂无批准数据
- King's College Hospital NHS Foundation Trust has recruited the first patient globally into the Takeda Pharmaceuticals TAK-226-3001 Phase 3 trial. - The trial evaluates erlitercept against standard-of-care erythropoietin for treating anaemia in adults with lower-risk Myelodysplastic Syndromes (MDS). - The study aims to recruit 300 patients globally, with participants able to remain in the trial for up to five years. - MDS affects around 4 in every 100,000 people in the UK, predominantly older adults, and carries an increased risk of progression to acute leukaemia.
- Researchers from ICR, King's College London, and King's College Hospital developed DOSET, a novel statistical framework for early-phase CAR-T therapy trials that simultaneously evaluates safety and efficacy. - DOSET demonstrated superior performance in correctly identifying safe and effective doses compared to existing methods, particularly in small-sample settings common in CAR-T studies. - The design allows trials to stop early when treatments appear ineffective or unsafe, reducing patient exposure to suboptimal doses. - Published in ESMO Open, DOSET marks the first publication of a novel statistical trial design from ICR-CTSU's Early Phase and Adaptive Trials Group for a real clinical trial.
- C-mo Medical Solutions has received CE Mark approval for its C-mo System, a Class IIa medical device that uses AI-powered algorithms to objectively monitor cough frequency, bouts, and intensity in patients aged 5 years and older. - The system demonstrated strong clinical validation with median sensitivity of 95.0% and specificity of 99.9% in cough event detection across more than 180 subjects in three clinical studies. - The technology addresses a significant unmet need in respiratory care, as chronic cough affects approximately 9.6% of adults worldwide and is associated with substantial quality of life impairment. - The approval supports broader adoption in clinical trials and medical practice, with initial commercial focus on pharmaceutical companies and research institutions seeking objective cough endpoints.
- i-Lumen Scientific received FDA Investigational Device Exemption approval to initiate U.S. enrollment in the i-SIGHT2 pivotal study evaluating bioelectric stimulation therapy for intermediate to advanced dry AMD. - The global trial will enroll 120 participants across multiple countries, with the first patient already treated in the United Kingdom and U.S. enrollment expected to begin in late April 2026. - The non-invasive therapy uses proprietary microcurrent stimulation delivered via electrodes to improve retinal pigment epithelium function and address underlying dry AMD pathology. - Previous feasibility data showed over 50% of treated patients achieved ≥2 lines of visual acuity improvement at 3 months, supporting advancement to this pivotal trial.
- ENDRA Life Sciences reported that its TAEUS Liver device achieved an intraclass correlation coefficient of 0.89 with 3.3% standard error of measurement in a clinical study evaluating measurement consistency for metabolic dysfunction-associated steatotic liver disease. - The study involved 14 subjects with independent operators performing 56 unique measurements to assess the device's repeatability and reproducibility in real-world clinical conditions. - The results demonstrate the device's potential to deliver MRI-level liver fat quantification at point of care with significantly lower cost than traditional MRI-PDFF, addressing barriers for over two billion people affected by MASLD. - The performance data contrasts sharply with traditional ultrasound techniques that suffer from high inter-observer variability and subjective interpretations.
- A groundbreaking base-edited CAR-T cell therapy called BE-CAR7 achieved 82% deep remission rates in patients with previously untreatable T-cell acute lymphoblastic leukemia. - Clinical trial results published in the New England Journal of Medicine show 64% of patients remain disease-free, with some now three years post-treatment. - The therapy uses advanced base-editing technology to create "universal" donor T-cells that can target and destroy leukemic T-cells without requiring patient matching. - Great Ormond Street Hospital Charity has committed over £2 million to support treatment for an additional 10 patients in an extended trial cohort.
- A pilot randomized controlled trial by King's College London found that preimplantation genetic testing for aneuploidy (PGT-A) resulted in a 72% cumulative live birth rate versus 52% in the control group among women aged 35-42. - Women who received PGT-A achieved pregnancy in fewer embryo transfers, reducing time to conception for this age group at higher risk of chromosomal abnormalities. - The study uniquely included mosaic embryos containing both normal and abnormal cells, addressing a gap in IVF research despite their common occurrence in clinical practice. - While results did not reach statistical significance due to the small sample size of 100 women, the findings warrant larger multi-center trials to validate the potential benefits.
